-
CLINICAL TRIAL EVIDENCE, EXPEDITED REGULATORY PATHWAYS, AND REVIEW EFFICIENCY OF RARE DISEASE DRUGS APPROVED IN CHINA, 2016-2025
Aug 11, 2026, 17:16 PM -
IMPACT OF COMORBIDITY BURDEN ON LONG-TERM QUALITY OF LIFE FOLLOWING SEVERE VIRAL LOWER RESPIRATORY TRACT DISEASE HOSPITALIZATION
Aug 11, 2026, 17:16 PM -
EVALUATING THE ECONOMIC AND ORGANIZATIONAL IMPACT OF SUBCUTANEOUS OCRELIZUMAB FOR MULTIPLE SCLEROSIS IN ALGERIA
Aug 11, 2026, 17:16 PM -
REAL-WORLD CORTICOSTEROID BURDEN REDUCTION WITH SUBCUTANEOUS IMMUNOGLOBULIN IGPRO20 IN CIDP
Aug 11, 2026, 17:16 PM -
EXTRACTING PATIENT-CENTRIC DISEASE PROGRESSION INSIGHTS FROM NORSTELLALINQ CLINICAL NOTES: MG-ADL SCORES IN MYASTHENIA GRAVIS USING UNSTRUCTURED REAL-WORLD DATA
Aug 11, 2026, 17:16 PM -
CHANGES IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND SUBSEQUENT RISK OF DEMENTIA: A NATIONWIDE COHORT STUDY
Aug 11, 2026, 17:16 PM -
FROM SELF-DIAGNOSIS TO PROFESSIONAL HELP-SEEKING: DSM-5-BASED ONLINE SCREENING FOR PORNOGRAPHY-WATCHING DISORDER
Aug 11, 2026, 17:16 PM -
HOW HAVE NICE COMMITTEES APPLIED THE NEW COST EFFECTIVENESS THRESHOLDS OF £25,000 TO £35,000 PER QALY?
Aug 11, 2026, 17:16 PM -
COST UTILITY ANALYSIS OF OBINUTUZUMAB BETA VERSUS OBINUTUZUMAB FOR PRIMARY MEMBRANOUS NEPHROPATHY IN CHINA: A MAIC-ADJUSTED MARKOV MODEL ANALYSIS
Aug 11, 2026, 17:16 PM -
COST MINIMIZATION ANALYSIS OF METYRAPONE VERSUS OSILODROSTAT FOR ENDOGENOUS CUSHING'S SYNDROME IN POLAND
Aug 11, 2026, 17:16 PM -
HEALTHCARE ACCESS AND BARRIERS AMONG RURAL POPULATIONS IN INDIA: A NARRATIVE REVIEW OF PATIENT-CENTERED AND ECONOMIC OUTCOMES
Aug 11, 2026, 17:16 PM -
EVALUATION OF ARTIFICIAL INTELLIGENCE TOOLS FOR THE CONSIDERATION OF AUTOMATION OR AUGMENTATION OF LITERATURE REVIEW PROCESSES AT NICE: A SCOPING REVIEW
Aug 11, 2026, 17:16 PM -
INFORMATION AVAILABILITY AMONG THE 34 AUTHORITIES AND BODIES IN THE JCA SUBGROUP
Aug 11, 2026, 17:16 PM -
BEYOND THE REFERENCE CASE: EXTENDING A NICE PRECEDENT TO CONSIDER QUANTIFIABLE EFFECTS ON OTHER NHS PATIENTS
Aug 11, 2026, 17:16 PM -
ECONOMIC BURDEN OF NON-CYSTIC FIBROSIS BRONCHIECTASIS IN EUROPE: EXACERBATIONS AND IMPLICATIONS FOR DISEASE PROGRESSION
Aug 11, 2026, 17:16 PM -
ANNUAL ECONOMIC BURDEN OF STROKE IN PATIENTS WITH TYPE 2 DIABETES IN TURKIYE: A PUBLIC PAYER PERSPECTIVE
Aug 11, 2026, 17:16 PM -
INVESTIGATING THE CORRELATION BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN FIRST-LINE (1L) CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
Aug 11, 2026, 17:16 PM -
JOINT CLINICAL ASSESSMENTS AND THE CHALLENGE OF EVALUATING MEDICINES WITH NON-TRADITIONAL EVIDENCE
Aug 11, 2026, 17:16 PM -
DRIVERS OF NEGATIVE HTA DECISIONS IN BETWEEN ENGLAND AND IRELAND: A DATA-DRIVEN REVIEW OF COST-EFFECTIVENESS SUBMISSIONS
Aug 11, 2026, 17:16 PM -
QUANTIFYING THE SOCIETAL VALUE OF RESMETIROM FOR METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS USING A SOCIETAL VALUE MODELING APPROACH
Aug 11, 2026, 17:16 PM
